Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,867 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Dental Caries
Interventions: C16G2 Gel, Placebo; Drug · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Esophageal Cancer
Interventions: Chemotherapy, Radiation Therapy, Surgery, MRI Imaging, Blood Draws; Radiation · Procedure · Device + 1 more
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC 68498, Placebo; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Acromegaly
Interventions: ALXN2420, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Torrance, California • Ann Arbor, Michigan

Conditions: Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions: NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations; Drug · Other
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more

Conditions: Cerebral Palsy
Interventions: APPLES-tele, Parent-centered Approach (PCA) Support Intervention, Standard of Care; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 4 Months to 13 Months
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Lung Cancer - Non Small Cell Squamous
Interventions: Ipilimumab, Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 33
States / cities: San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more

Conditions: Child Abuse, Child Neglect
Interventions: Promoting First Relationships ®, Resource & Referral; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metabolic Syndrome
Interventions: PP-MI Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Revere, Massachusetts

Conditions: Lymphoma, Large Cell, Diffuse
Interventions: Zevalin; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 60 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Cocaine Dependence, Alcohol Dependence
Interventions: Real cTBS, Sham cTBS; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Schizophrenia
Interventions: TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Conditions: Penile Diseases
Interventions: RestoreX PTT - randomized and open label, RestoreX PTT - open label phase only; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions: AGuIX, Radiotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017, naproxen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: MyoRegulator®; Device
Lead sponsor: PathMaker Neurosystems Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Obesity, Overweight
Interventions: Lifestyle Modification Intervention, Balanced Calorie Deficit Eating Plan, Ad Libitum Whole Food Plant-Based Eating Plan; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol Use Disorder, Insomnia
Interventions: Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence; Drug · Behavioral · Device
Lead sponsor: Sterling McPherson; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Aged
Interventions: Lifestyle Redesign; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 60 Years and older
Enrollment: 460 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis (MS)
Interventions: Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Migraine
Interventions: Treximet, Placebo; Drug
Lead sponsor: Premiere Research Institute; Other
Eligibility: 12 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more

Search by objective public record fields.

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Families Together: Intervention for Reunified Families

Developing a Positive Psychology Intervention to Promote Health Behaviors in Metabolic Syndrome: RCT

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

10 Days of Theta Burst Stimulation as a Tool to Treat Cocaine Dependence

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Efficacy of Penile Traction Therapy Using a Novel Device

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Early Feasibility Study of the MyoRegulator® for Treatment of ALS

Remotely Delivered Behavioral Weight Loss Using an Ad Libitum Plant-Based Diet Versus a Balanced Calorie Deficit Diet

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

USC Well Elderly Study 2

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Treximet Early Intervention Adolescent Migraine